

Arthur Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1758625/publications.pdf>

Version: 2024-02-01

75
papers

1,571
citations

304368

22
h-index

344852

36
g-index

82
all docs

82
docs citations

82
times ranked

2625
citing authors

#	ARTICLE	IF	CITATIONS
1	Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. <i>Cell Reports</i> , 2022, 38, 110236.	2.9	14
2	Predicting treatment outcomes using ¹⁸ F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	1.4	7
3	Profile of vascular markers and CT enhancement of hyaline vascular type Castleman's disease. <i>Microvascular Research</i> , 2022, 142, 104357.	1.1	1
4	Serum glucose excretion after Roux-en-Y gastric bypass: a potential target for diabetes treatment. <i>Gut</i> , 2021, 70, 1847-1856.	6.1	19
5	Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative ¹⁸ F-FDG PET/CT in patients with localized primary gastrointestinal stromal tumors. <i>Cancer & Metabolism</i> , 2021, 9, 8.	2.4	9
6	Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S245-S252.	0.7	0
7	Splenic uptake on FDG PET/CT correlates with Kikuchi-Fujimoto disease severity. <i>Scientific Reports</i> , 2021, 11, 10836.	1.6	8
8	STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [¹⁸ F]FLT PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	11
9	Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. <i>Cell Chemical Biology</i> , 2020, 27, 197-205.e6.	2.5	16
10	Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 561-571.	3.3	12
11	Choroid Plexus as the Best Reference Region for Standardized Uptake Value Analysis on C11-Acetate PET/CT for Grading and Predicting Prognosis in Patients with Cerebral Gliomas. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 274-280.	0.6	5
12	Altered systematic glucose utilization after gastrectomy: correlation with weight loss. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 900-907.	1.0	4
13	Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer. <i>Lung Cancer</i> , 2020, 142, 28-33.	0.9	16
14	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 113-122.	2.7	16
15	Radiologic Diagnosis (CT, MRI, & PET-CT). , 2019, , 67-86.		1
16	The prognostic value of volume-based parameters using ¹⁸ F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018, 21, 213-224.	2.7	32
17	Evaluation of ¹⁸ F-FDG PET/CT Parameters for Detection of Lymph Node Metastasis in Cutaneous Melanoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 39-45.	0.6	14
18	Regulation of Acetate Utilization by Monocarboxylate Transporter 1 (MCT1) in Hepatocellular Carcinoma (HCC). <i>Oncology Research</i> , 2018, 26, 71-81.	0.6	25

#	ARTICLE	IF	CITATIONS
19	Usefulness of SPECT/CT in Parathyroid Lesion Detection in Patients with Thyroid Parenchymal ^{99m} Tc-Sestamibi Retention. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 32-39.	0.6	17
20	Correlation between KRAS mutation and ¹⁸ F-FDG uptake in stage IV colorectal cancer. <i>Abdominal Radiology</i> , 2017, 42, 1621-1626.	1.0	19
21	Intestinal Glycolysis Visualized by FDG PET/CT Correlates With Glucose Decrement After Gastrectomy. <i>Diabetes</i> , 2017, 66, 385-391.	0.3	14
22	Feasibility of Preoperative FDG PET/CT Total Hepatic Glycolysis in the Remnant Liver for the Prediction of Postoperative Liver Function. <i>American Journal of Roentgenology</i> , 2017, 208, 624-631.	1.0	10
23	Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1984-1994.	3.3	12
24	Value of ¹⁸ F-FDG PET/CT for Predicting the World Health Organization Malignant Grade of Thymic Epithelial Tumors. <i>Clinical Nuclear Medicine</i> , 2016, 41, 15-20.	0.7	29
25	Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 347-353.	0.7	23
26	Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 116-125.	0.7	11
27	Reply. <i>American Journal of Ophthalmology</i> , 2016, 163, 198-199.	1.7	0
28	Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer. <i>Tumor Biology</i> , 2016, 37, 3205-3213.	0.8	3
29	Correlation between EGFR gene mutation, cytologic tumor markers, ¹⁸ F-FDG uptake in non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 224.	1.1	54
30	Prognostic value of ¹⁸ F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 279-286.	1.2	16
31	Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer. <i>Annals of Nuclear Medicine</i> , 2016, 30, 104-113.	1.2	53
32	Increased hepatic FDG uptake on PET/CT in hepatic sinusoidal obstructive syndrome. <i>Oncotarget</i> , 2016, 7, 69024-69031.	0.8	8
33	Prognostic Impact of Ultrasonography Features and ¹⁸ F-Fluorodeoxyglucose Uptake in Patients With Papillary Thyroid Microcarcinoma. <i>Clinical and Experimental Otorhinolaryngology</i> , 2016, 9, 62-69.	1.1	3
34	A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas. <i>Cancer Research and Treatment</i> , 2016, 48, 409-414.	1.3	6
35	Prognostic value of pretreatment FDG PET in pediatric neuroblastoma. <i>European Journal of Radiology</i> , 2015, 84, 2633-2639.	1.2	26
36	Predictive value of bone scintigraphy for the detection of joint involvement in Behçet's disease: Dermatologists' perspectives. <i>European Journal of Dermatology</i> , 2015, 25, 477-482.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1494-1500.	2.8	13
38	Association Between Choroidal Thickness and Metabolic Activity on Positron Emission Tomography in Eyes With Choroidal Melanoma. <i>American Journal of Ophthalmology</i> , 2015, 160, 1111-1115.e2.	1.7	7
39	18F-fluoride PET imaging in a nude rat model of bone metastasis from breast cancer: Comparison with 18F-FDG and bioluminescence imaging. <i>Nuclear Medicine and Biology</i> , 2015, 42, 728-733.	0.3	4
40	Thyroid incidentalomas detected on 18F-fluorodeoxyglucose-positron emission tomography/computed tomography: Thyroid Imaging Reporting and Data System (TIRADS) in the diagnosis and management of patients. <i>Surgery</i> , 2015, 158, 1314-1322.	1.0	23
41	The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. <i>Annals of Nuclear Medicine</i> , 2015, 29, 400-408.	1.2	25
42	The Performance of Contrast-Enhanced FDG PET/CT for the Differential Diagnosis of Unexpected Ovarian Mass Lesions in Patients With Nongynecologic Cancer. <i>Clinical Nuclear Medicine</i> , 2015, 40, 97-102.	0.7	12
43	Prognostic Value of Total Lesion Glycolysis by ¹⁸ F-FDG PET/CT in Surgically Resected Stage IA Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 45-49.	2.8	77
44	Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 108-114.	0.6	12
45	⁶⁴ Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model. <i>PLoS ONE</i> , 2015, 10, e0131083.	1.1	6
46	Clinicopathologic Features and Molecular Characteristics of Glucose Metabolism Contributing to ¹⁸ F-fluorodeoxyglucose Uptake in Gastrointestinal Stromal Tumors. <i>PLoS ONE</i> , 2015, 10, e0141413.	1.1	25
47	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4113-4113.	0.8	0
48	Clinical correlations with 18FDG PET scan patterns in solid pseudopapillary tumors of the pancreas: Still a surgical enigma?. <i>Pancreatology</i> , 2014, 14, 515-523.	0.5	21
49	The Additional Value of Attenuation Correction CT Acquired During 18F-FDG PET/CT in Differentiating Mature From Immature Teratomas. <i>Clinical Nuclear Medicine</i> , 2014, 39, e193-e196.	0.7	7
50	18F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. <i>Annals of Nuclear Medicine</i> , 2014, 28, 304-313.	1.2	23
51	Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. <i>Biomaterials</i> , 2014, 35, 2272-2282.	5.7	84
52	Clinical Usefulness of 18F-Fluorodeoxyglucose-Positron Emission Tomography in Patients With Locally Advanced Pancreatic Cancer Planned to Undergo Concurrent Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 126-133.	0.4	41
53	The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1898-1906.	3.3	63
54	Surgical completeness of robotic thyroidectomy: a prospective comparison with conventional open thyroidectomy in papillary thyroid carcinoma patients. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 1068-1075.	1.3	52

#	ARTICLE	IF	CITATIONS
55	The Role of 18F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 130-136.	0.6	34
56	REGRESSION OF UVEAL MELANOMA AFTER RU-106 BRACHYTHERAPY AND THERMOTHERAPY BASED ON METABOLIC ACTIVITY MEASURED BY POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY. <i>Retina</i> , 2014, 34, 182-187.	1.0	5
57	Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 257-262.	0.6	10
58	Evaluation of 18F-FDG Excretion Patterns in Malignant Obstructive Uropathy. <i>Clinical Nuclear Medicine</i> , 2013, 38, 695-702.	0.7	5
59	NSCLC Subtype Prediction Using Cytologic Fluid Specimens From Needle Aspiration Biopsies. <i>American Journal of Clinical Pathology</i> , 2013, 139, 309-316.	0.4	6
60	Prognostic Value of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer. <i>Yonsei Medical Journal</i> , 2013, 54, 1377.	0.9	28
61	Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 169-175.	0.6	21
62	Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. <i>European Radiology</i> , 2011, 21, 1077-1087.	2.3	23
63	Reply to Letter to Editor re: usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. <i>European Radiology</i> , 2011, 21, 2150-2150.	2.3	0
64	Using 18F-FDG PET/CT to Detect an Occult Mesenchymal Tumor Causing Oncogenic Osteomalacia. <i>Nuclear Medicine and Molecular Imaging</i> , 2011, 45, 233-237.	0.6	10
65	Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using 18F-FDG PET/CT and 99mTc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation. <i>Nuclear Medicine and Molecular Imaging</i> , 2011, 45, 203-211.	0.6	13
66	Association of high metabolic activity measured by positron emission tomography imaging with poor prognosis of choroidal melanoma. <i>British Journal of Ophthalmology</i> , 2011, 95, 1588-1591.	2.1	9
67	The Utility of F-18 FDG PET/CT in the Evaluation of Pancreatic Intraductal Papillary Mucinous Neoplasm. <i>Clinical Nuclear Medicine</i> , 2010, 35, 776-779.	0.7	66
68	Physiologic ¹⁸ F-FDG Uptake in the Fallopian Tubes at Mid Cycle on PET/CT. <i>Journal of Nuclear Medicine</i> , 2010, 51, 682-685.	2.8	22
69	Visually Discernible [18F]Fluorodeoxyglucose Uptake in Papillary Thyroid Microcarcinoma: A Potential New Risk Factor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3182-3188.	1.8	43
70	High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 2426-2432.	3.2	85
71	Measurement of Donor Kidney Functional Renal Volume and Glomerular Filtration Rate to Predict Allograft Function during the Post-Transplantation Period. <i>Nephron Clinical Practice</i> , 2009, 113, c262-c269.	2.3	12
72	Radiation Safety Issues Related to Sentinel Lymph Node Biopsy using Radioactive Colloid: Commentary on "Exposure of Surgical Staff to Radiation". <i>Journal of Breast Cancer</i> , 2009, 12, 121.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Thyroid Incidentalomas Identified by ¹⁸ F-FDG PET: Sonographic Correlation. American Journal of Roentgenology, 2008, 191, 598-603.	1.0	50
74	Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. Journal of Nuclear Medicine, 2005, 46, 1582-8.	2.8	117
75	Altered Glucose Metabolism and Glucose Transporters in Systemic Organs After Bariatric Surgery. Frontiers in Endocrinology, 0, 13, .	1.5	1